These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35215963)

  • 1. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic.
    Harfoot R; Lawley B; Hernández LC; Kuang J; Grant J; Treece JM; LeQueux S; Day R; Jack S; Stanton JL; Bostina M; Ussher JE; Quiñones-Mateu ME
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Response to SARS-CoV-2 in Aotearoa New Zealand: Implementation of a Diagnostic Test and Characterization of the First COVID-19 Cases in the South Island.
    Lawley B; Grant J; Harfoot R; Treece JM; Day R; Hernández LC; Stanton JL; Ussher JE; Quiñones-Mateu ME
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and characterization of an early SARS-CoV-2 isolate from the 2020 epidemic in Medellín, Colombia.
    Díaz FJ; Aguilar-Jiménez W; Flórez-Álvarez L; Valencia G; Laiton-Donato K; Franco-Muñoz C; Álvarez-Díaz D; Mercado-Reyes M; Rugeles MT
    Biomedica; 2020 Oct; 40(Supl. 2):148-158. PubMed ID: 33152198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
    Cheng YW; Chao TL; Li CL; Wang SH; Kao HC; Tsai YM; Wang HY; Hsieh CL; Lin YY; Chen PJ; Chang SY; Yeh SH
    mBio; 2021 Aug; 12(4):e0058721. PubMed ID: 34311586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shedding of Viable Virus in Asymptomatic SARS-CoV-2 Carriers.
    Murata T; Sakurai A; Suzuki M; Komoto S; Ide T; Ishihara T; Doi Y
    mSphere; 2021 May; 6(3):. PubMed ID: 34011679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of SARS-CoV-2 from COVID-19 Patients and an Asymptomatic Individual.
    Hishiki T; Usui K; An T; Suzuki R; Sakuragi JI; Tanaka Y; Matsuki Y; Kawai J; Kogo Y; Hayashizaki Y; Takasaki T
    Jpn J Infect Dis; 2022 May; 75(3):277-280. PubMed ID: 34719530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations.
    Jacob JJ; Vasudevan K; Pragasam AK; Gunasekaran K; Veeraraghavan B; Mutreja A
    mBio; 2021 Aug; 12(4):e0118821. PubMed ID: 34281387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and genetic characterization of SARS-CoV-2 from Indian patients in a single family without H/O travel abroad.
    Shrivastava S; Patil HP; Mhaske ST; Palkar S; Lalwani S; Mishra AC; Arankalle VA
    Virus Genes; 2021 Jun; 57(3):245-249. PubMed ID: 33683658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of SARS-CoV-2 infectivity of upper respiratory specimens from COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells.
    Yamada S; Fukushi S; Kinoshita H; Ohnishi M; Suzuki T; Fujimoto T; Saijo M; Maeda K;
    BMJ Open Respir Res; 2021 Feb; 8(1):. PubMed ID: 33627333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of SARS-CoV-2 isolated from COVID-19 family clusters.
    Gunadi ; Wibawa H; Hakim MS; Marcellus ; Trisnawati I; Khair RE; Triasih R; Irene ; Afiahayati ; Iskandar K; Siswanto ; Anggorowati N; Daniwijaya EW; Supriyati E; Nugrahaningsih DAA; Budiono E; Retnowulan H; Puspadewi Y; Puspitawati I; Sianipar O; Afandy D; Simanjaya S; Widitjiarso W; Puspitarani DA; Fahri F; Riawan U; Fauzi AR; Kalim AS; Ananda NR; Setyati A; Setyowireni D; Laksanawati IS; Arguni E; Nuryastuti T; Wibawa T;
    BMC Med Genomics; 2021 Jun; 14(1):144. PubMed ID: 34074255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive Parallel Sequencing.
    Alessandrini F; Caucci S; Onofri V; Melchionda F; Tagliabracci A; Bagnarelli P; Di Sante L; Turchi C; Menzo S
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ultrastructural and genomic study on the SARS-CoV-2 variant B.1.210 circulating during the first wave of COVID-19 pandemic in India.
    Kumar N; Santhoshkumar R; Prasad P; George AK; Aiyar J; Joshi S; Narayanappa G; Desai AS; Ravi V; Venkataswamy MM
    Indian J Med Microbiol; 2023; 41():45-52. PubMed ID: 36870749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing of SARS-CoV-2 in local transmission cases through Oxford Nanopore MinION platform from Karachi Pakistan.
    Mukry SN; Ahmed S; Raza Bukhari A; Shahni A; Sufaida G; Naz A; Shamsi TS
    J Infect Dev Ctries; 2021 Oct; 15(10):1376-1383. PubMed ID: 34780358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome sequencing of SARS-CoV-2 reveals the detection of G614 variant in Pakistan.
    Umair M; Ikram A; Salman M; Khurshid A; Alam M; Badar N; Suleman R; Tahir F; Sharif S; Montgomery J; Whitmer S; Klena J
    PLoS One; 2021; 16(3):e0248371. PubMed ID: 33755704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication.
    Fahnøe U; Pham LV; Fernandez-Antunez C; Costa R; Rivera-Rangel LR; Galli A; Feng S; Mikkelsen LS; Gottwein JM; Scheel TKH; Ramirez S; Bukh J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene.
    Pyke AT; Nair N; van den Hurk AF; Burtonclay P; Nguyen S; Barcelon J; Kistler C; Schlebusch S; McMahon J; Moore F
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Ramirez S; Fernandez-Antunez C; Galli A; Underwood A; Pham LV; Ryberg LA; Feng S; Pedersen MS; Mikkelsen LS; Belouzard S; Dubuisson J; Sølund C; Weis N; Gottwein JM; Fahnøe U; Bukh J
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0009721. PubMed ID: 33903110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.
    Virtanen J; Uusitalo R; Korhonen EM; Aaltonen K; Smura T; Kuivanen S; Pakkanen SH; Mero S; Patjas A; Riekkinen M; Kantele A; Nurmi V; Hedman K; Hepojoki J; Sironen T; Huhtamo E; Vapalahti O
    Viruses; 2021 May; 13(6):. PubMed ID: 34073577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.